|
Inflammatory Bowel Diseases
|
0.300 |
Biomarker
|
group |
MGD |
|
|
|
|
Adult T-Cell Lymphoma/Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-2 production by primary adult T cell leukemia tumor cells is macrophage dependent.
|
1288288 |
1992 |
|
Leukemia, T-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interleukin-2 production by primary adult T cell leukemia tumor cells is macrophage dependent.
|
1288288 |
1992 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
After interleukin-2 expansion of TIL from renal and lung carcinoma and melanoma biopsy tissues, rearrangements of TCR beta-chain genes were analyzed by Southern blotting.
|
1314129 |
1992 |
|
Carcinoma of lung
|
0.090 |
Biomarker
|
disease |
BEFREE |
After interleukin-2 expansion of TIL from renal and lung carcinoma and melanoma biopsy tissues, rearrangements of TCR beta-chain genes were analyzed by Southern blotting.
|
1314129 |
1992 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
It remains to be established whether IL-2 production occurs in the normal pituitary or is intrinsic to the process of tumor development of these cells.
|
1331177 |
1992 |
|
Adenoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Interleukin-2 and interleukin-2 receptor expression in human corticotrophic adenoma and murine pituitary cell cultures.
|
1331177 |
1992 |
|
Acute lymphocytic leukemia
|
0.090 |
Biomarker
|
disease |
BEFREE |
Expression of selected human HOX-2 genes in B/T acute lymphoid leukemia and interleukin-2/interleukin-1 beta-stimulated natural killer lymphocytes.
|
1351762 |
1992 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Expression of selected human HOX-2 genes in B/T acute lymphoid leukemia and interleukin-2/interleukin-1 beta-stimulated natural killer lymphocytes.
|
1351762 |
1992 |
|
Asthma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Levels of IL-1 beta (266 +/- 270 pg/ml versus less than 20 pg/ml) (p = 0.001) and IL-2 (1.4 +/- 2.8 ng/ml versus less than 0.3 ng/ml) (p = 0.05) in BALF in patients with symptomatic compared with that in BALF levels in patients with asymptomatic asthma suggested activation of alveolar macrophages and T cells.
|
1374772 |
1992 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies have examined the efficacy of using combinations of interferons, interleukin-2, or specific subpopulations of lymphoid cells to control metastatic renal cell carcinoma.
|
1379830 |
1992 |
|
Metastatic Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies have examined the efficacy of using combinations of interferons, interleukin-2, or specific subpopulations of lymphoid cells to control metastatic renal cell carcinoma.
|
1379830 |
1992 |
|
Leukemia, T-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phenotypic changes induced by interleukin-2 (IL-2) and IL-3 in an immature T-lymphocytic leukemia are associated with regulated expression of IL-2 receptor beta chain and of protein tyrosine kinases LCK and LYN.
|
1379847 |
1992 |
|
Hairy Cell Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Hairy cell leukemia is a chronic lymphoproliferative disorder characterized by the expansion of neoplastic B-cells expressing the p55 chain of the interleukin 2 receptor (IL-2R) system that is recognized by anti-CD25 monoclonal antibodies (mAb) and binds interleukin 2 (IL-2) with low affinity.
|
1394125 |
1992 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A cDNA library of tumour cells was screened with an interleukin 2 gene-specific probe.
|
1396583 |
1992 |
|
T-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma.
|
1396583 |
1992 |
|
Hepatitis B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Following mitogen exposure HBV DNA levels increased above pre-stimulation levels in 19/25 PHA cultures, 6/15 ConA cultures, 1/15 LPS cultures, and 1/15 IL2 cultures.
|
1402824 |
1992 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Leukemic cells from six out of 17 T-ALL/T-cell non-Hodgkin's lymphoma patients with a prothymocyte (stage I) or a mature thymocyte (stage III), but not with a common thymocyte (stage II) phenotype, could proliferate, in a dose-dependent manner, in response to recombinant IL2 (rIL2) and anti-Tac and TU27 moAbs as well as polyclonal anti-IL2 purified immunoglobulin G could inhibit this IL2-induced cell proliferation.
|
1405755 |
1992 |
|
Head and Neck Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
The epithelial growth factors, EGF and TGF-alpha, which share the same receptor, EGFR, may play a pivotal role in the development and maintenance of head and neck cancer; preliminary studies concerning TGF-beta and IL-2 are inconclusive.
|
1408194 |
1992 |
|
Malignant Head and Neck Neoplasm
|
0.080 |
Biomarker
|
disease |
BEFREE |
The epithelial growth factors, EGF and TGF-alpha, which share the same receptor, EGFR, may play a pivotal role in the development and maintenance of head and neck cancer; preliminary studies concerning TGF-beta and IL-2 are inconclusive.
|
1408194 |
1992 |
|
Diphtheria
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously shown that the variable domains of the monoclonal antibody anti-Tac [anti-Tac(Fv)] can be fused to derivatives of Pseudomonas exotoxin (PE) or diphtheria toxin (DT) to produce recombinant immunotoxins that kill interleukin-2 (IL-2) receptor-bearing cells.
|
1421405 |
1992 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia.
|
1421405 |
1992 |
|
Malignant neoplasm of kidney
|
0.400 |
Biomarker
|
disease |
BEFREE |
Depending on the cell line and the vector construct used, lymphokine gene-modified human RC cell lines released 4 to 29 units/10(6) cells of IL-2, or up to 10 units/10(6) cells of IFN-gamma within 48 h. Fluorescence-activated cell sorter analysis of SK-RC-29 cells releasing IFN-gamma showed increased expression of major histocompatibility complex class I antigen, beta 2-microglobulin, and ICAM-1, as well as induction of major histocompatibility complex class II antigen expression [human leukocyte antigen(HLA)-DR, -DP], but no changes in these cell surface markers were observed with SK-RC-29 cells releasing IL-2.
|
1423266 |
1992 |
|
Renal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Depending on the cell line and the vector construct used, lymphokine gene-modified human RC cell lines released 4 to 29 units/10(6) cells of IL-2, or up to 10 units/10(6) cells of IFN-gamma within 48 h. Fluorescence-activated cell sorter analysis of SK-RC-29 cells releasing IFN-gamma showed increased expression of major histocompatibility complex class I antigen, beta 2-microglobulin, and ICAM-1, as well as induction of major histocompatibility complex class II antigen expression [human leukocyte antigen(HLA)-DR, -DP], but no changes in these cell surface markers were observed with SK-RC-29 cells releasing IL-2.
|
1423266 |
1992 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We noted: (a) a significant difference in the frequency of A11 (20.5% versus 10.2%; P < 0.05) allele between melanoma patients and the North American Caucasian population; (b) a significantly higher frequency of A11 phenotype among responders (40.5%) than in the melanoma patient population (20.5%; P < 0.01), which was even more obvious among patients responding to TIL therapy (47.4% versus 22.1%; P < 0.05); within TIL patients, responders also had an increased frequency of A19 (42.1% versus 25.6%; P < 0.05); (c) a correlation between the number of TILs received and response rate (P < 0.005); and (d) an association between DR4 haplotype and decreased tolerance to IL-2 among the patients receiving TILs (P = 0.01).
|
1423301 |
1992 |